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Materials and Methods: Candidates for the study were recurrence-
free patients treated with primary radiotherapy (IMRT) for oral, 
pharyngeal and laryngeal cancer from 2006 to 2011 and attending 
follow-up between January1st and May 7th 2012. A total of 65 patients 
(44%) accepted the invitation to participate in a follow-up study 
including Modified Barium Swallow (MBS), EORTC QLQ C30 and H&N35, 
mouth opening, Charlsons co-morbidity index and smoking status. 
Data on patient, tumor and treatment characteristics were obtained 
from the DAHANCA database: Larynx 37%, pharynx 52%, oral cavity 
11%; median age 63 years, 85% men, 57% stage IV disease; weekly 
cisplatin 41%, Zalutumumab 16%. DVHs of the following OARs were 
analyzed: pharyngeal constrictor muscles (sup, mid. and inf. PCM), 
cricopharyngeal muscle, esophagus inlet muscle (EIM), cervical 
esophagus (CE), base of tongue, glottic and supraglottic larynx. Data 
were analyzed with dichotomized endpoints and logistic regression 
models. 
Results: Median follow-up after treatment was 3.3 years (range 1.0 - 
5.3).There was no significant difference between participants and 
non-participants regarding patient, tumor and treatment 
characteristics, as well as maximum DAHANCA score for early and late 
dysphagia. The most frequent objective swallowing dysfunction was 
retention on MBS, occurring in 41 of the 65 patients (63%)[Table 1]. 
Penetration and aspiration was less common, 31% and 6%, 
respectively. The QoL data showed low degree of dysphagia with 
mean scores of 11-13, respectively. In general the different endpoints 
did not correlate well with each other indicating that they describe 
different aspects of swallowing morbidity. This difference was 
reflected in the correlations between swallowing endpoints and dose 
to the OAR. In general, complications observed on MBS and observer 
assessed late dysphagia correlated with the dose to superior and 
middle PCM (all p-values below 0.04), whereas quality of life 
endpoints correlated with dose-volume parameters in the larynx and 
supraglottic larynx (p values below 0.05).  
 
  
Conclusions: In this cohort of patients treated with IMRT, a high rate 
of retention was found on MBS whereas most other dysphagia-related 
endpoints occurred with a lower frequency. Significant relationships 
between dysphagia measures and dose-volume characteristics were 
found for specific OARs, especially the superior and middle PCM. 
Dysphagia is not sufficiently described using a single endpoint. 
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Purpose/Objective: To determine the impact of intensity-modulated 
radiotherapy (IMRT) in developing post-treatment hypothyroidism in 
nasopharyngeal carcinoma (NPC) patients, and to investigate the 
possible factors that could predict the onset of hypothyroidism. 
Materials and Methods: We retrospectively collected thyroid function 
of patient received radiotherapy for nasopharyngeal carcinoma at our 
hospital. Between January 2000 to December 2008, 191 patients were 
included into our study. There were 142 males and 49 females, with 
the median age of 48 years old. Table 1 summarized the 
characterisitcs of patients and treatment. Thyroid function was 
evaluated by measuring thyroid stimulating hormone (TSH) and serum 
free thyroxine(FT4). Elevated TSH level is documented as subclinical 
hypothyroidism and low level of FT4 is classified as clinical 
hypothyroidism. The risk factors analyzed in this study included age, 
gender, pathology, tumor and nodal extent, treatment modality, re-
irradiation, and chemotherapy. 
 
  
Results: With a median follow-up of 5.24 years (range, 0.18-12.2 
years), the incidence rates of clinical hypothyroidism in entire 
patients were 9.9%, 21.8 % and 43.3%, respectively in 3 years, 5 years, 
and 10 years follow up. In univariate analysis, subclinical 
hypothyroidism was more common in younger age (<30 years vs. 30 
years; P=0.022), advanced N stage (N3b vs. N0-3a; P=0.005), and IMRT 
group (IMRT vs. conventional radiotherapy; P<0.001). (Figure 1) While 
advanced T stage (T3-4 vs. T1-2; P<0.001), advanced N stage (N3b vs. 
N0-3a; P=0.045), and IMRT (IMRT vs. conventional radiotherapy; 
P<0.001) were significant factors that determine clinical 
hypothyroidism. IMRT group remained significant in developing both 
clinical (P<0.001) and subclinical (P<0.001) hypothyroidism in 
multivariate analysis while compared to traditional radiotherapy 
technique. The incidence rates of clinical hypothyroidism in IMRT 
group were 14.7 %, 42.3 % and 61.5 %, respectively in 3 years, 5 years, 
and 8 years follow up. 
 
  
Conclusions: More than half of NPC patients will experience clinical 
hypothyroidism after the treatment of IMRT. To avoid irreversibe 
damage, it is mandatory to set the proper dose constrain for thyroid 
organ in the future IMRT plan. 
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Purpose/Objective: Normal tissue biology may change during 
radiotherapy affecting function of organs at risk. The purpose of the 
study was to evaluate the changes of volume and proliferation level of 
